Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955292 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Cylene Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00955292 is a Phase 1 study that was terminated before completion, run by Cylene Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT00955292, a Phase 1 study, was terminated before completion, sponsored by Cylene Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.
Interventions
- DRUG Quarfloxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955292
The ClinicalTrials.gov registry entry for NCT00955292 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cylene Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quarfloxin is the first listed.
NCT00955292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955292 about?
NCT00955292 is a clinical study titled "Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas". This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.
What is the current status of trial NCT00955292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00955292?
The interventions under investigation include: Quarfloxin (DRUG).
Who is sponsoring clinical trial NCT00955292?
This trial is sponsored by Cylene Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.